Drug Interactions between Benefiber (guar gum formulation) and ezogabine
This report displays the potential drug interactions for the following 2 drugs:
- Benefiber (guar gum formulation) (guar gum)
- ezogabine
Interactions between your drugs
No interactions were found between Benefiber (guar gum formulation) and ezogabine. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Benefiber (guar gum formulation)
A total of 39 drugs are known to interact with Benefiber (guar gum formulation).
- Benefiber (guar gum formulation) is in the drug class laxatives.
ezogabine
A total of 464 drugs are known to interact with ezogabine.
- Ezogabine is in the drug class neuronal potassium channel openers.
- Ezogabine is used to treat the following conditions:
Drug and food interactions
guar gum food
Applies to: Benefiber (guar gum formulation) (guar gum)
ADJUST DOSING INTERVAL: Bulk-forming laxatives such as guar gum, psyllium, polycarbophil, or methylcellulose may affect the bioavailability of concomitantly administered substances due to their effect on the rate of gastrointestinal transit and gastric emptying.
MANAGEMENT: In general, oral medications should be administered at least 2 hours before or 2 hours after dosing of the bulk-forming laxative.
References (1)
- (2001) "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals
ezogabine food
Applies to: ezogabine
GENERALLY AVOID: Alcohol may increase the plasma concentrations of ezogabine. In a study of healthy volunteers, the administration of ezogabine 200 mg in combination with ethanol 1g/kg (5 standard alcohol drinks) over 20 minutes resulted in an increase in the ezogabine peak plasma concentration (Cmax) and systemic exposure (AUC) by 23% and 37%, respectively.
Food does not significantly affect the bioavailability of ezogabine. According to the product labeling, high-fat food does not affect the extent to which ezogabine is absorbed, but increases peak plasma concentration (Cmax) by approximately 38% and delays the time to reach peak concentration (Tmax) by 0.75 hour.
MANAGEMENT: In general, alcohol consumption should be avoided or limited during treatment with CNS-depressant agents. Patients should be advised of the potential for increased dose-related adverse reactions of ezogabine (e.g., dizziness, somnolence, nausea, constipation, urinary retention, blurred vision, memory impairment, tremor) when taken with alcohol, and to avoid hazardous activities that require mental alertness and motor coordination until they know how the medication affects them. Ezogabine can be taken with or without food.
References (1)
- (2011) "Product Information. Potiga (ezogabine)." GlaxoSmithKline
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.